

# CITATION REPORT

List of articles citing

## Recurrence, Progression, and Follow-Up in NonMuscle-Invasive Bladder Cancer

DOI: 10.1016/j.eursup.2009.06.010  
European Urology Supplements, 2009, 8, 556-562.

**Source:** <https://exaly.com/paper-pdf/47048887/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
48	Current intravesical therapy for non-muscle invasive bladder cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13, 1371-85	5.4	22
47	[How to apply follow-up in relation to risk group]. <i>Urologia</i> , <b>2013</b> , 80 Suppl 21, 42-7	1.2	
46	Determination of Bacillus Calmette-Guerin Concentration Integrated in Delivery Materials for Intravesical Infusion Therapy of Superficial Bladder Cancer. <i>Advanced Materials Research</i> , <b>2013</b> , 655-657, 1917-1922	0.5	0
45	Increased upper and lower tract urothelial carcinoma in patients with end-stage renal disease: a nationwide cohort study in Taiwan during 1997-2008. <i>BioMed Research International</i> , <b>2014</b> , 2014, 149750 <sup>3</sup>		21
44	Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validity study of two independent patient cohorts. <i>BMC Urology</i> , <b>2014</b> , 14, 36	2.2	18
43	<sup>11</sup> C-choline PET/CT and bladder cancer: lymph node metastasis assessment with pathological specimens as reference standard. <i>Clinical Nuclear Medicine</i> , <b>2015</b> , 40, e124-8	1.7	27
42	Detection of urinary bladder cancer cells using redox ratio and double excitation wavelengths autofluorescence. <i>Biomedical Optics Express</i> , <b>2015</b> , 6, 977-86	3.5	23
41	Impact of Glycemic Control and Metformin Use on the Recurrence and Progression of Non-Muscle Invasive Bladder Cancer in Patients with Diabetes Mellitus. <i>Journal of Korean Medical Science</i> , <b>2016</b> , 31, 1464-71	4.7	13
40	External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non -muscle invasive bladder cancer stages Ta and T1. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , <b>2016</b> , 42, 932-941	2	5
39	Improving hyperthermia treatment planning for the pelvis by accurate fluid modeling. <i>Medical Physics</i> , <b>2016</b> , 43, 5442	4.4	16
38	Changes in autofluorescence based organoid model of muscle invasive urinary bladder cancer. <i>Biomedical Optics Express</i> , <b>2016</b> , 7, 1193-200	3.5	11
37	Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer. <i>International Urology and Nephrology</i> , <b>2016</b> , 48, 993-9	2.3	24
36	EORTC Risk Model to Predict Progression in Patients With Non-Muscle-Invasive Bladder Cancer: Is It Safe to Use in Clinical Practice?. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 176-82	3.3	15
35	Updates for the radiologist in non-muscle-invasive, muscle-invasive, and metastatic bladder cancer. <i>Abdominal Radiology</i> , <b>2017</b> , 42, 2710-2724	3	5
34	Tissue-engineered human 3D model of bladder cancer for invasion study and drug discovery. <i>Biomaterials</i> , <b>2017</b> , 145, 233-241	15.6	28
33	Comparative Effectiveness of Fluorescent Versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , <b>2017</b> , 197, 548-558	2.5	50
32	Image-Guided Transurethral Resection of Bladder Tumors - Current Practice and Future Outlooks. <i>Bladder Cancer</i> , <b>2017</b> , 3, 149-159	1	19

31	MicroRNA Expression Profile Identifies High Grade, Non-Muscle-Invasive Bladder Tumors at Elevated Risk to Progress to an Invasive Phenotype. <i>Genes</i> , <b>2017</b> , 8,	4.2	12
30	Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis. <i>Bladder Cancer</i> , <b>2018</b> , 4, 91-112	1	21
29	Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study. <i>American Journal of Clinical Nutrition</i> , <b>2018</b> , 107, 208-216	7	12
28	Grading, Staging, and Morphologic Risk Stratification of Bladder Cancer. <i>Molecular Pathology Library</i> , <b>2018</b> , 29-42		1
27	Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection. <i>Journal of Urology</i> , <b>2018</b> , 199, 655-662	2.5	32
26	EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification. <i>Medicine (United States)</i> , <b>2018</b> , 97, e12006	1.8	3
25	Modeling human bladder cancer. <i>World Journal of Urology</i> , <b>2018</b> , 36, 1759-1766	4	8
24	Cancer survivorship in Deutschland Epidemiologie und Definitionen. <b>2019</b> , 34, 158-164	0.2	9
23	Diagnostic and prognostic roles of CK20 in the pathology of urothelial lesions. A systematic review. <i>Pathology Research and Practice</i> , <b>2019</b> , 215, 152413	3.4	3
22	The UroLife study: protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle-invasive bladder cancer prognosis and health-related quality of life. <i>BMJ Open</i> , <b>2019</b> , 9, e030396	3	1
21	Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study. <i>Frontiers in Genetics</i> , <b>2019</b> , 10, 1237	4.5	21
20	Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 86-96	2.8	7
19	Recurrence of Subepithelial Non-Muscle Invasive Bladder Cancer Following Transurethral Resection: A Case Report. <i>Journal of the Korean Society of Radiology</i> , <b>2021</b> , 82, 715	0.2	
18	Extracellular Vesicles as Biomarkers Carriers in Bladder Cancer: Diagnosis, Surveillance, and Treatment. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
17	Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 161-170	2.8	8
16	Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma. <i>Cancer Cell International</i> , <b>2021</b> , 21, 226	6.4	2
15	Literatur. <b>2021</b> , 179-184		
14	Targeting Hsp90 in urothelial carcinoma. <i>Oncotarget</i> , <b>2015</b> , 6, 8454-73	3.3	22

13	Downregulation of ST3GAL5 is associated with muscle invasion, high grade and a poor prognosis in patients with bladder cancer. <i>Oncology Letters</i> , <b>2020</b> , 20, 828-840	2.6	6
12	Ureteropyeloscopic Treatment of Upper Urinary Tract Urothelial Malignancy. <b>2015</b> , 35-51		
11	Uromonitor <sup>®</sup> as a novel sensitive and specific urine-based test for recurrence surveillance of patients with non-muscle invasive bladder cancer.		1
10	“Cancer survivorship” <i>Best Practice Onkologie</i> , <b>2020</b> , 15, 64-70	0	0
9	DataSheet_1.docx. <b>2019</b> ,		
8	Video_1.mp4. <b>2019</b> ,		
7	The potential mechanism of Longsheyangquan Decoction on the treatment of bladder cancer: Systemic network pharmacology and molecular docking. <i>Frontiers in Pharmacology</i> , 13,	5.6	1
6	A Diagnostic Gene Expression Signature for Bladder Cancer Can Stratify Cases into Prescribed Molecular Subtypes and Predict Outcome. <i>Diagnostics</i> , <b>2022</b> , 12, 1801	3.8	0
5	Impact of Effective Intravesical Therapies on Quality of Life in Patients with Non-Muscle Invasive Bladder Cancer: A Systematic Review. <b>2022</b> , 19, 10825		0
4	Development of a new two-arm transurethral surgical system for en bloc resection of bladder tumor: A preclinical study.		0
3	Evaluation of direct intramural injection to the bladder wall as a method for developing orthotopic tumor models. <b>2022</b> , 5, 575-581		0
2	Clinical and treatment characteristics of secondary bladder malignancies following low dose rate brachytherapy for prostate cancer. <b>2023</b> ,		0
1	Urological Cancers. <b>2023</b> , 117-137		0